en · de · es · fr · pt
peptide-index.peptides9002.com › Wiki › Administration, Testing And Availability — Quick Reference

Administration, Testing And Availability — Quick Reference

By Editorial Desk · published 2025-08-26 · last reviewed 2025-09-17 · Wiki

Selank raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-17. Anything still debated is marked as such rather than presented as settled.

Administration, Testing and Availability

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Selank at a glance

PropertyValueNotes
Common routeIntranasalAlso injected in some animal work
Solubility classFreely soluble in waterSolid form is hygroscopic
Typical storageAbout -20 degrees CelsiusKeep desiccated and dark
Purity methodReverse-phase HPLCReported as area percent
Confirmatory methodMass spectrometryVerifies expected molecular mass

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Related pages on this site

Analytical Methods And Storage Stability

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Further detail

In addition, various side effects, including insomnia, sedation, weight loss, constipation, dry mouth, erectile dysfunction, excessive sweating, and urinary retention, among others, have been found to be around twice as frequent in poor metabolizers relative to extensive metabolizers. The same was true for discontinuation rates (11.2% vs. 6.3%). In terms of dosage adjustment for CYP2D6 poor metabolizers or those taking strong CYP2D6 inhibitors, the Food and Drug Administration (FDA) label says that this may be necessary and provides directions for this, whereas literature reviews state that it is not considered necessary based on clinical trial experience.

Sargramostim, sold under the brand name Leukine among others, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator. It is administered via intravenous infusion or via subcutaneous injection.

However, this final plan was prevented by the fall of the Peruvian Dictatorship of Bolívar in 1827, the Peruvian Intervention in Bolivia in 1828 for the fall of Sucre, and later the Dissolution of Gran Colombia after the Gran Colombian-Peruvian War. Not without Bolívar previously accusing the populations of Peru and Bolivia as "the despicable peoples of the South who allowed themselves to be drawn into the civil war or were seduced by the enemies."Finally, the antecedents of the Gran Colombo-Peruvian War are considered by many historians as the maximum evidence of Bolívar's anti-Peruvianism. It is reported that his acts of government left much to be desired and were even harmful to the Peruvian indigenous population, for which he imprisoned or shot guerrillas who had helped him in the campaigns in the mountains. To the indigenous people, to whom he dedicated his worst insults, he reimposed the indigenous tribute (which had been abolished in the viceroyalty with the constitution of Cádiz) and weakened their peasant communities with the abolition of the Cacicazgos in the young Republic of Peru, breaking thus definitively a hierarchical system of the Inca nobility that had been present, for more than 3 centuries in Peru, for the protection of the economic interests of the Indian against a nascent Gamonalismo.

Sources: en.wikipedia.org

Supporting material

=== Misinformation === Naloxone has been subject to much inaccurate media reporting and many urban legends about it have become prevalent. One such myth is that naloxone makes the recipient violent. Another is that events called "Lazarus parties" have taken place, in which people reportedly took fatal overdoses in anticipation of being treated with naloxone; in reality this was a fiction spread by the police. Yet another is the claim that people have indulged in "yo-yoing", whereby they would take naloxone and opioids simultaneously to enjoy an extreme "high" and subsequent revival; the idea is scientifically nonsensical.

18 May – Former Conservative cabinet minister Michael Gove tells BBC Scotland's The Sunday Show that he does not believe a second Scottish independence referendum is necessary, but that it could happen if there was "overwhelming support" for one. David Clews, a conspiracy theorist and far-right influencer, and Mark Collett, a Nazi-sympathiser who set up the far-right Patriotic Alternative, have called for supporters to "infiltrate" Reform UK following its recent success to push their own "pro-white" and anti-immigration agenda. 20 May – Starmer apologises to Liz Saville-Roberts, Plaid Cymru's leader at Westminster, after saying at the previous week's Prime Minister's Questions that "she talks rubbish". 21 May – Conservative Garry Perry resigns as leader of Walsall Council with immediate effect after what he describes as a "campaign of political attrition, deliberate undermining, and personal hostility". Tameside Council appoints Brenda Warrington, whose involvement in a controversial WhatsApp group led to the suspension of several Labour councillors and MPs, as its standards watchdog. 22 May – Reform UK are accused of "blatant" racism by Scottish Labour over an online advert which says that Anas Sarwar will "prioritise the Pakistani community". Welsh Labour expels Cardiff councillor Keith Jones after an investigation found he had sexually harassed a teenager. 23 May – Conservative leader Kemi Badenoch says she cannot commit to fully restoring winter fuel payments to pensioners.

==== 2020s ==== In August 2025, Teva released the first generic version of a GLP-1 semaglutide product, named Saxenda. Saxenda is not a generic version of semaglutide (Ozempic) which is within patent protection. Saxenda is a generic of an older medication, liraglutide, that has been found to cause thyroid cancer in rats but with no evidence this risk extends to humans.

Sources: en.wikipedia.org

Frequently asked questions

How is the peptide typically administered in studies?

Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.

What do the human studies show?

Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.

How is sample identity verified?

Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Network